Corium International, Inc. (NASDAQ:CORI) CAO Timothy D. Sweemer sold 12,012 shares of the company’s stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $7.62, for a total transaction of $91,531.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Timothy D. Sweemer also recently made the following trade(s):

  • On Wednesday, August 16th, Timothy D. Sweemer sold 15,488 shares of Corium International stock. The shares were sold at an average price of $7.82, for a total transaction of $121,116.16.

Shares of Corium International, Inc. (NASDAQ:CORI) traded up 0.13% on Friday, hitting $7.63. The company had a trading volume of 106,567 shares. The stock’s 50-day moving average is $8.30 and its 200 day moving average is $5.79. Corium International, Inc. has a 52 week low of $2.67 and a 52 week high of $9.57. The company’s market capitalization is $272.71 million.

Corium International (NASDAQ:CORI) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.13. The company had revenue of $8.11 million for the quarter, compared to analysts’ expectations of $8.71 million. Corium International had a negative net margin of 145.60% and a negative return on equity of 673.17%. Equities analysts expect that Corium International, Inc. will post ($1.69) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Corium International, Inc. (CORI) CAO Sells $91,531.44 in Stock” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/08/18/corium-international-inc-cori-cao-sells-91531-44-in-stock.html.

Several research firms have recently commented on CORI. Jefferies Group LLC reaffirmed a “buy” rating and set a $8.00 price target on shares of Corium International in a research report on Wednesday, July 19th. WBB Securities raised shares of Corium International to a “buy” rating and set a $13.00 price target for the company in a research report on Friday, July 7th. BidaskClub lowered shares of Corium International from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Zacks Investment Research lowered shares of Corium International from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Finally, ValuEngine raised shares of Corium International from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $11.79.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Broadfin Capital LLC boosted its position in shares of Corium International by 45.2% in the first quarter. Broadfin Capital LLC now owns 2,787,121 shares of the biopharmaceutical company’s stock valued at $11,650,000 after buying an additional 867,400 shares in the last quarter. AWM Investment Company Inc. boosted its position in shares of Corium International by 1,125.9% in the first quarter. AWM Investment Company Inc. now owns 2,451,700 shares of the biopharmaceutical company’s stock valued at $10,248,000 after buying an additional 2,251,700 shares in the last quarter. Perceptive Advisors LLC bought a new position in shares of Corium International during the first quarter valued at $11,096,000. Royce & Associates LP boosted its position in shares of Corium International by 208.4% in the first quarter. Royce & Associates LP now owns 548,464 shares of the biopharmaceutical company’s stock valued at $2,293,000 after buying an additional 370,600 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Corium International by 118.1% in the first quarter. Bank of New York Mellon Corp now owns 25,269 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 13,683 shares in the last quarter. Institutional investors own 75.63% of the company’s stock.

About Corium International

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.